These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 25493569)

  • 1. PDE3A-SLCO1C1 locus is associated with response to anti-tumor necrosis factor therapy in psoriatic arthritis.
    Julià A; Rodríguez J; Fernández-Sueiro JL; Gratacós J; Queiró R; Montilla C; Torre-Alonso JC; Pérez-Venegas JJ; Manrique-Arija S; Muñoz-Fernández S; González C; Roig D; Zarco P; Erra A; Castañeda S; García A; Salvador G; Díaz-Torne C; Blanco R; Domínguez AW; Mosquera JA; Vela P; Tornero J; Sánchez-Fernández S; Corominas H; Ramírez J; Avila G; Alonso A; Tortosa R; López-Lasanta M; Cañete JD; Marsal S
    Pharmacogenomics; 2014 Nov; 15(14):1763-1769. PubMed ID: 25493569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GWAS replication study confirms the association of PDE3A-SLCO1C1 with anti-TNF therapy response in rheumatoid arthritis.
    Acosta-Colman I; Palau N; Tornero J; Fernández-Nebro A; Blanco F; González-Alvaro I; Cañete JD; Maymó J; Ballina J; Fernández-Gutiérrez B; Olivé A; Corominas H; Erra A; Canela-Xandri O; Alonso A; López Lasanta M; Tortosa R; Julià A; Marsal S
    Pharmacogenomics; 2013 May; 14(7):727-34. PubMed ID: 23651021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of the PDE3A-SLCO1C1 locus with the response to anti-TNF agents in psoriasis.
    Julià A; Ferrándiz C; Dauden E; Fonseca E; Fernández-López E; Sanchez-Carazo JL; Vanaclocha F; Puig L; Moreno-Ramírez D; Lopez-Estebaranz JL; Herrera E; de la Cueva P; Ávila G; Alonso A; Tortosa R; López-Lasanta M; Marsal S
    Pharmacogenomics J; 2015 Aug; 15(4):322-5. PubMed ID: 25403996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Previously reported PDE3A-SLCO1C1 genetic variant does not correlate with anti-TNF response in a large UK rheumatoid arthritis cohort.
    Smith SL; Plant D; Lee XH; Massey J; Hyrich K; Morgan AW; Wilson AG; Isaacs J; Barton A
    Pharmacogenomics; 2016 May; 17(7):715-20. PubMed ID: 27180831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF{kappa}B signalling pathways.
    Potter C; Cordell HJ; Barton A; Daly AK; Hyrich KL; Mann DA; Morgan AW; Wilson AG; ; Isaacs JD
    Ann Rheum Dis; 2010 Jul; 69(7):1315-20. PubMed ID: 20448286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.
    Finckh A; Ciurea A; Brulhart L; Kyburz D; Möller B; Dehler S; Revaz S; Dudler J; Gabay C;
    Arthritis Rheum; 2007 May; 56(5):1417-23. PubMed ID: 17469098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Periarticular bone gain at proximal interphalangeal joints and changes in bone turnover markers in response to tumor necrosis factor inhibitors in rheumatoid and psoriatic arthritis.
    Szentpetery A; McKenna MJ; Murray BF; Ng CT; Brady JJ; Morrin M; Radovits B; Veale DJ; Fitzgerald O
    J Rheumatol; 2013 May; 40(5):653-62. PubMed ID: 23457381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Body mass does not affect the remission of psoriatic arthritis patients on anti-TNF-α therapy.
    Iannone F; Fanizzi R; Scioscia C; Anelli MG; Lapadula G
    Scand J Rheumatol; 2013; 42(1):41-4. PubMed ID: 22991950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heart rate variability predicts anti-tumor necrosis factor therapy response for inflammatory arthritis.
    Holman AJ; Ng E
    Auton Neurosci; 2008 Dec; 143(1-2):58-67. PubMed ID: 18632310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients.
    Seitz M; Wirthmüller U; Möller B; Villiger PM
    Rheumatology (Oxford); 2007 Jan; 46(1):93-6. PubMed ID: 16720636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
    Braun-Moscovici Y; Markovits D; Rozin A; Toledano K; Nahir AM; Balbir-Gurman A
    Isr Med Assoc J; 2008 Apr; 10(4):277-81. PubMed ID: 18548981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FCGR2A/CD32A and FCGR3A/CD16A variants and EULAR response to tumor necrosis factor-α blockers in psoriatic arthritis: a longitudinal study with 6 months of followup.
    Ramírez J; Fernández-Sueiro JL; López-Mejías R; Montilla C; Arias M; Moll C; Alsina M; Sanmarti R; Lozano F; Cañete JD
    J Rheumatol; 2012 May; 39(5):1035-41. PubMed ID: 22467926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relationship between synovial lymphocyte aggregates and the clinical response to infliximab in rheumatoid arthritis: a prospective study.
    Klaasen R; Thurlings RM; Wijbrandts CA; van Kuijk AW; Baeten D; Gerlag DM; Tak PP
    Arthritis Rheum; 2009 Nov; 60(11):3217-24. PubMed ID: 19877042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody response is reduced following vaccination with 7-valent conjugate pneumococcal vaccine in adult methotrexate-treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors.
    Kapetanovic MC; Roseman C; Jönsson G; Truedsson L; Saxne T; Geborek P
    Arthritis Rheum; 2011 Dec; 63(12):3723-32. PubMed ID: 21834061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumour necrosis factor (TNF)-blocking agents in juvenile psoriatic arthritis: are they effective?
    Otten MH; Prince FH; Ten Cate R; van Rossum MA; Twilt M; Hoppenreijs EP; Koopman-Keemink Y; Oranje AP; de Waard-van der Spek FB; Gorter SL; Armbrust W; Dolman KM; Wulffraat NM; van Suijlekom-Smit LW
    Ann Rheum Dis; 2011 Feb; 70(2):337-40. PubMed ID: 21068101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic risk and protective factors of TNFSF15 gene variants detected using single nucleotide polymorphisms in Hungarians with psoriasis and psoriatic arthritis.
    Képíró L; Széll M; Kovács L; Keszthelyi P; Kemény L; Gyulai R
    Hum Immunol; 2014 Feb; 75(2):159-62. PubMed ID: 24269700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycosylation status of serum in inflammatory arthritis in response to anti-TNF treatment.
    Collins ES; Galligan MC; Saldova R; Adamczyk B; Abrahams JL; Campbell MP; Ng CT; Veale DJ; Murphy TB; Rudd PM; Fitzgerald O
    Rheumatology (Oxford); 2013 Sep; 52(9):1572-82. PubMed ID: 23681398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peripheral blood expression of nuclear factor-kappab-regulated genes is associated with rheumatoid arthritis disease activity and responds differentially to anti-tumor necrosis factor-alpha versus methotrexate.
    Parker A; Izmailova ES; Narang J; Badola S; Le T; Roubenoff R; Ginsburg GS; Maier A; Coblyn JS; Shadick NA; Weinblatt ME
    J Rheumatol; 2007 Sep; 34(9):1817-22. PubMed ID: 17696278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of anti-TNF treatment initiation in rheumatoid arthritis databases demonstrates wide country variability in patient parameters at initiation of anti-TNF therapy.
    Pease C; Pope JE; Truong D; Bombardier C; Widdifield J; Thorne JC; Paul Haraoui B; Psaradellis E; Sampalis J; Bonner A
    Semin Arthritis Rheum; 2011 Aug; 41(1):81-9. PubMed ID: 21168187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.